Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Zymeworks Inc Is A Clinical-Stage Biopharmaceutical Company Dedicated To The Discovery, Development And Commercialization Of Next-Generation Multifunctional Biotherapeutics. Its Suite Of Therapeutic Platforms And Its Fully Integrated Drug Development Engine Enables Precise Engineering Of Differentiated Therapeutic Product Candidates. Its Clinical Candidate, Zanidatamab, Is A Novel Her2-Targeted Bispecific Antibody Currently Being Evaluated In Multiple Phase 1, Phase 2, And Pivotal Clinical Trials Globally As A Targeted Treatment Option For Patients With Solid Tumors That Express Her2. It Is Also Advancing A Deep Preclinical Pipeline In Oncology And Other Therapeutic Areas.